Movano health submits response to fda as part of final review phase for eviemed

Company remains optimistic on the potential for this pioneering healthcare solution pleasanton, calif. , nov. 4, 2024 /prnewswire/ -- movano health (nasdaq: move ) announced today that it has submitted a complete response package to the fda as part of the final phase of the company's 510(k) application review of the eviemed ring.

MOVE Ratings Summary

MOVE Quant Ranking